Brief: CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026

CRISM Therapeutics

30/10/2025 07:24

Oct 30 (Reuters) - CRISM' Therapeutics Corp CRTX.L:

CRISM THERAPEUTICS  - US ORPHAN DRUG DESIGNATION APPLICATION

CRISM' THERAPEUTICS CORP - PHASE 2 CLINICAL TRIAL FOR IRINOTECAN-CHEMOSEED TO BEGIN IN Q1 2026

CRISM' THERAPEUTICS CORP - CRISM SUBMITS APPLICATION FOR ORPHAN DRUG DESIGNATION TO FDA

Source text: ID:nRSd4097Fa

Further company coverage: CRTX.L

 ((Reuters.Briefs@thomsonreuters.com;;))